In Spring 2019, the LT Murray Family Foundation, a charitable organization based in Washington state that primarily supports programs in the Puget Sound area, made a generous contribution to The Geneva Foundation (Geneva) in support of the first small grant competition for researchers at Joint Base Lewis-McChord (JBLM). Throughout April, Geneva received ten competitive applications
Category: Mission in Action
The Uniformed Services University (USU) recently issued a Cooperative agreement to Geneva to facilitate the execution of the Collaboratory for Musculoskeletal Injury Rehabilitation Research (CMIRR). CMIRR is a four-year, $15M program funded by the Defense Health Agency (DHA), with the purpose of improving a rehabilitative approach to caring for military service members with musculoskeletal injury
The Fort Bragg Research Institute (FBRI) originated from the recognized need to link the vast infrastructure of science and technology regionally available to Womack Army Medical Center (WAMC) with the growing needs of operational readiness for Fort Bragg, NC. Areas of research interest include biomarker discovery for mild traumatic brain injury, machine learning to assist medics
The 4-Dimensional Bioprinting, Biofabrication, and Biomanufacturing (4D Bio3) Program is a five-year program funded by the Defense Health Program (DHP), with the purpose of promoting the development and application of advanced bioprinting, biofabrication, and biomanufacturing technologies for research pursuant to Department of Defense (DoD) priorities and ultimately for translation to clinical medical defense care and training solutions.
Geneva is proud to announce the launch of its newest program, the Fort Bragg Research Institute (FBRI). The FBRI was established to link the infrastructure of science and technology regionally available to Womack Army Medical Center (WAMC) and the increasing needs of operational readiness at Fort Bragg, NC.
Exxell BIO, Inc. joins consortium in collaboration with Geneva, Thomas Jefferson University, USAMRIID, IDT Biologika, and IDRI for preparation and vaccine formulation testing for protection against the Ebola, Sudan, Marburg, and Lassa fever viruses. These deadly viruses, categorized as hemorrhagic fever viruses, display varying symptoms that typically appear 2-21 days after exposure, and can include
Phelix Therapeutics is launching a collaboration with The Geneva Foundation and The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for continued research of a treatment for SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) via Phelix’s “novel viral fusion inhibitors for treating SARS/MERS coronaviruses”. SARS and MERS are coronaviruses
The Jonas Center for Nursing and Veterans Healthcare announced a partnership to support Geneva’s first scholarship for nursing research to advance military medicine. The scholarship will fund a Johns Hopkins School of Nursing doctoral candidate whose goal is to transform the diagnosis process for Post-Traumatic Stress Disorder (PTSD) – an area of scientific study with potential for